Refine
Year of publication
Document Type
- Preprint (62)
- Article (51)
- Part of Periodical (3)
- Working Paper (1)
Has Fulltext
- yes (117)
Is part of the Bibliography
- no (117)
Keywords
- Bibliographie (3)
- Film (3)
- Hadron-Hadron Scattering (3)
- Heavy Ions (3)
- Charm physics (2)
- ALICE experiment (1)
- ATM (1)
- Anti-seizure medication (1)
- BFIS (1)
- Beauty production (1)
Institute
Die Lichtabsorptionseigenschaften einer Reihe von Lösungen der Komplexionen des dreiwertigen Vanadins vom Typus [V A6]3+, wo A H2O, CH3OH, C2H5OH sowie iso-C4H9OH ist, wurden gemessen. Ferner wurden die Absorptionsspektren von kristallisiertem Ammonium-sowie Caesiumvanadin(III)-alaun aufgenommen.
Intensitätsverhältnisse und spektrale Lage der in allen Spektren auftretenden langwelligen Banden stehen in guter Übereinstimmung mit den Aussagen der Theorie für den Fall eines Zentralions mit zwei d-Elektronen bei Oh-Symmetrie des Komplexfeldes.
The transcription factor ∆Np63 is a master regulator of epithelial cell identity and essential for the survival of squamous cell carcinoma (SCC) of lung, head and neck, oesophagus, cervix and skin. Here, we report that the deubiquitylase USP28 stabilizes ∆Np63 and maintains elevated ∆NP63 levels in SCC by counteracting its proteasome‐mediated degradation. Impaired USP28 activity, either genetically or pharmacologically, abrogates the transcriptional identity and suppresses growth and survival of human SCC cells. CRISPR/Cas9‐engineered in vivo mouse models establish that endogenous USP28 is strictly required for both induction and maintenance of lung SCC. Our data strongly suggest that targeting ∆Np63 abundance via inhibition of USP28 is a promising strategy for the treatment of SCC tumours.
Background: The approval of everolimus (EVE) for the treatment of angiomyolipoma (2013), subependymal giant cell astrocytoma (2013) and drug-refractory epilepsy (2017) in patients with tuberous sclerosis complex (TSC) represents the first disease-modifying treatment option available for this rare and complex genetic disorder. Objective: The objective of this study was to analyse the use, efficacy, tolerability and treatment retention of EVE in patients with TSC in Germany from the patient’s perspective. Methods: A structured cross-age survey was conducted at 26 specialised TSC centres in Germany and by the German TSC patient advocacy group between February and July 2019, enrolling children, adolescents and adult patients with TSC. Results: Of 365 participants, 36.7% (n = 134) reported the current or past intake of EVE, including 31.5% (n = 115) who were taking EVE at study entry. The mean EVE dosage was 6.1 ± 2.9 mg/m2 (median: 5.6 mg/m2, range 2.0–15.1 mg/m2) in children and adolescents and 4 ± 2.1 mg/m2 (median: 3.7 mg/m2, range 0.8–10.1 mg/m2) in adult patients. An early diagnosis of TSC, the presence of angiomyolipoma, drug-refractory epilepsy, neuropsychiatric manifestations, subependymal giant cell astrocytoma, cardiac rhabdomyoma and overall multi-organ involvement were associated with the use of EVE as a disease-modifying treatment. The reported efficacy was 64.0% for angiomyolipoma (75% in adult patients), 66.2% for drug-refractory epilepsy, and 54.4% for subependymal giant cell astrocytoma. The overall retention rate for EVE was 85.8%. The retention rates after 12 months of EVE therapy were higher among adults (93.7%) than among children and adolescents (88.7%; 90.5% vs 77.4% after 24 months; 87.3% vs 77.4% after 36 months). Tolerability was acceptable, with 70.9% of patients overall reporting adverse events, including stomatitis (47.0%), acne-like rash (7.7%), increased susceptibility to common infections and lymphoedema (each 6.0%), which were the most frequently reported symptoms. With a total score of 41.7 compared with 36.8 among patients not taking EVE, patients currently being treated with EVE showed an increased Liverpool Adverse Event Profile. Noticeable deviations in the sub-items ‘tiredness’, ‘skin problems’ and ‘mouth/gum problems’, which are likely related to EVE-typical adverse effects, were more frequently reported among patients taking EVE. Conclusions: From the patients’ perspective, EVE is an effective and relatively well-tolerated disease-modifying treatment option for children, adolescents and adults with TSC, associated with a high long-term retention rate that can be individually considered for each patient. Everolimus therapy should ideally be supervised by a centre experienced in the use of mechanistic target of rapamycin inhibitors, and adverse effects should be monitored on a regular basis.
Die FOURIER-Nullkomponente der Bindungsmatrix Gij G(0) in 1 Beziehung (5.16) wurde durch Summation spezieller Diagramme in der sogen. „Kettenapproximation“ und der „Wassermelonenapproximation“ näherungsweise berechnet. Auf der Basis von (5.16) in 1 wurde in der Kettenapproximation und der Wassermelonenapproximation die magnetische Suszeptibilität und die Magnetisierung des dreidimensionalen ISING-Modells bestimmt. In der Kettenapproximation wurden ferner die freie Energie, die innere Energie und die Atomwärme des dreidimensionalen ISING-Ferromagneten sowie die Druck-Dichte-Isothermen des dreidimensionalen Gittergases ausgerechnet.
Die „Selbstenergien“ Gn in 1 wurden durch näherungsweise Auswertung einer größeren Klasse von Selbstenergiediagrammen approximativ berechnet. Das Gleichungssystem (3.3) in 1 für die renormierten Semiinvarianten wurde umgeformt und durch zusätzliche Näherungsannahmen vereinfacht. Durch Näherungsansätze für die Semiinvarianten M2, M3,... konnten einfache Gleichungen für die Magnetisierung M1 hergeleitet werden. Diese Gleichungen wurden numerisch gelöst. Auf der Grundlage der Beziehungen (3.5) und (4.8) in 1 wurden ferner die innere Energie, die freie Energie und die Atomwärme des zweidimensionalen Ising-Ferromagneten sowie die Druck-Dichte-Isothermen des zweidimensionalen Gittergases numerisch ausgerechnet.
Pathogenic variants in PRRT2, encoding the proline-rich transmembrane protein 2, have been associated with an evolving spectrum of paroxysmal neurologic disorders. Based on a cohort of children with PRRT2-related infantile epilepsy, this study aimed at delineating the broad clinical spectrum of PRRT2-associated phenotypes in these children and their relatives. Only a few recent larger cohort studies are on record and findings from single reports were not confirmed so far. We collected detailed genetic and phenotypic data of 40 previously unreported patients from 36 families. All patients had benign infantile epilepsy and harbored pathogenic variants in PRRT2 (core cohort). Clinical data of 62 family members were included, comprising a cohort of 102 individuals (extended cohort) with PRRT2-associated neurological disease. Additional phenotypes in the cohort of patients with benign sporadic and familial infantile epilepsy consist of movement disorders with paroxysmal kinesigenic dyskinesia in six patients, infantile-onset movement disorders in 2 of 40 individuals, and episodic ataxia after mild head trauma in one girl with bi-allelic variants in PRRT2. The same girl displayed a focal cortical dysplasia upon brain imaging. Familial hemiplegic migraine and migraine with aura were reported in nine families. A single individual developed epilepsy with continuous spikes and waves during sleep. In addition to known variants, we report the novel variant c.843G>T, p.(Trp281Cys) that co-segregated with benign infantile epilepsy and migraine in one family. Our study highlights the variability of clinical presentations of patients harboring pathogenic PRRT2 variants and expands the associated phenotypic spectrum.